double expressing diffuse large B-cell lymphoma
Conditions
Interventions
Group1:zanubrutinib plus R-CHOP
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged = 6 months; 6. Liver function: alanine aminotransferase (AST) and aspartate aminotransferase (ALT) = 3.0 x 10^9/L, neutrophil absolute value (ANC) >= 1.5 x 10^9/L, platelet (PLT) >= 75 x 10^9/L, hemoglobin (Hb) >= 90 g/L; 9. Cardiac function: Echocardiography of left ventricular ejection fraction (LVEF) >= 50%; 10. Sign informed Consent.
Exclusion criteria
Exclusion criteria: 1. Patients with primary central nervous system lymphoma; 2. Severe diseases that may limit the patient's participation in this trial (e.g., advanced infections, uncontrolled diabetes, uncontrolled hypertension, severe cardiac or angina, hepatic or renal insufficiency, etc.); 3. A history of other tumors, except cured cervical carcinoma in situ, basal cell carcinoma of the skin or squamous cell carcinoma of the skin; 4. Hiv-infected persons (HIV-positive); 5. Acute or chronic active hepatitis B and HBV DNA > 1*104; 6. A history of severe neurological or psychiatric problems, including dementia or epilepsy; 7. Patients who have already received chemotherapy for DLBCL, except for short course and low dose hormone; 8. The researchers considered it inappropriate to enroll.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| one year progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;CRR;Side effect; | — |
Countries
China
Contacts
Public ContactZou Liqun
West China Hospital, Sichuan University
Outcome results
None listed